CLINICAL RESEARCH POSTER PRESENTATION ABSTRACTS
Please note: All posters will be displayed in Salons 10-12.

THURSDAY, 5:30-6:15 PM


Taibi DM, Bourguignon C, Taylor AG.

A randomized clinical trial of the effects of Valerian on sleep disturbances in persons with arthritis.

University of Washington School of Nursing dmtaibi@u.washington.edu

PURPOSE: This pilot study was a double-blind, placebo-controlled, randomized clinical trial to investigate whether or not the valerian root extract, an herbal supplement, reduced sleep disturbances in persons with arthritis.

METHODS: Participants were randomly assigned to receive either valerian extract (600 mg) or a placebo (600 mg vegetable oil). Sleep outcomes were measured for eight days, including three days of baseline measurement and five days using the intervention one hour before bedtime. Objective sleep outcomes (sleep efficiency, number of awakenings, and sleep latency) were measured wrist actigraphs. Subjective sleep outcomes (sleep quality and estimated sleep latency) and daily pain were measured using daily diaries. Serum was collected for liver function tests and C-reactive protein (to measure general inflammation) at baseline and follow-up.

RESULTS: Fifteen participants were recruited from physicians' offices and the community in central Virginia. Primary analyses did not demonstrate significant effects on sleep efficiency, awakenings, subjective sleep latency, or sleep quality. Significant differences were found over time in objective sleep latency (p=.03), but latency was higher in the valerian group. This result may have occurred due to low baseline sleep latency. No clinically important changes occurred in the primary sleep outcomes. However, a greater proportion of persons in the valerian group than the placebo group believed that they received the valerian or were unsure (71.6% versus 50%), indicating that valerian may have exerted perceivable effects that were not evident on the outcomes used in this study. Secondary analyses supported the safety of valerian. Side effects were infrequent and mild. Liver function tests and C-reactive protein were unchanged by valerian.

CONCLUSIONS: Overall, these findings did not demonstrate that valerian effectively reduced sleep disturbances in the current sample of persons with arthritis. Various study limitations, particularly high intra-individual variability in sleep outcomes and use of a short supplementation period, may have reduced the sensitivity of the analyses in detecting potential treatment effects. However, the study supported the safety and tolerability of valerian and the feasibility of the study design. It remains possible that valerian could be useful as a mild sleep aid in this population, but further research is needed to support use of this herbal supplement as a sleep aid and to guide clinical recommendations.

 

Back